Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), affects approximately 2533% of the global population
The most famous female tennis player of our time is on a GLP-1 drug
Eleven percent had treated diabetes, 20% were on therapy for obstructive sleep apnea (OSAS), 30% were treated for hypertension, 11% had managed dyslipidemia, 23% reported arthralgia, and 22% had hepatopathy
Patients were made aware of the increased risk of hypoglycaemia that occurs when GLP-1 RAs are added to insulin therapy, due to effects on gluconeogenesis and glycogen stores in the liver, and were advised to be vigilant
But like all medications, it comes with side effects
GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound, liraglutide/Saxenda) are not DEA-scheduled drugs